Clinical trial
Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's…
NCT00005592 · University of Alabama at Birmingham, Other · Completed
Key facts
| NCT number | NCT00005592 |
|---|---|
| Title | Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma |
| Official title | A Multicenter, Open-Label, Trial to Evaluate the Efficacy and Safety of IDEC-Y2B8 Radioimmunotherapy of Relapsed or Refractory Low-Grade or Follicular Transformed B-Cell Non-Hodgkin's Lymphoma |
| Lead sponsor | University of Alabama at Birmingham, Other |
| Collaborators | National Cancer Institute (NCI) NIH Biogen Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological, Radiation |
| Interventions | 90-Y-ibritumomab tiuxetan, rituximab, indium In 111 ibritumomab tiuxetan |
| Enrollment | 23 |
| Start date | Nov 1, 1999 |
| Primary completion | Mar 1, 2002 |
| Completion | Nov 1, 2005 |
| First posted | Dec 16, 2003 |
| Last update posted | Oct 21, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: